ArticleScientific reports2025
Myelin basic protein and occludin may be the biomarkers to diagnose leukoaraiosis and cognitive dysfunction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Leukoaraiosis (LA) can lead to a range of clinical symptoms, with cognitive dysfunction being the most prominent. However, the biomarkers that could assist in the early diagnosis of LA and predict disease progression are lacking. Myelin basic protein (MBP), a key component of the myelin sheath, and Occludin (OCLN), a critical tight junction protein maintaining blood-brain barrier (BBB) integrity, are released into circulation upon white matter and BBB damage, making them promising candidate biomarkers. Clinical data and blood samples were collected from 99 healthy individuals and 99 patients with LA. The levels of myelin basic protein (MBP) and occludin (OCLN) in peripheral blood were measured in both groups, and the correlation between these proteins and clinical features was analyzed. The levels of MBP and OCLN in the peripheral blood of the LA group were significantly elevated compared to those of the control group. The MBP and OCLN possessed outstanding diagnostic accuracy. Importantly, MBP level showed a positive correlation with the severity of LA, and a significant correlation was observed between MBP and cognitive function. MBP and OCLN may serve as biomarkers for LA, with MBP showing potential value in diagnosing LA-associated cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.